medRxiv preprint doi: https://doi.org/10.1101/2020.10.08.20209304; this version posted October 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

porpotate	•
It is made available under a CC-BY	4.0 International license .

- **1** Prevalence of COVID-19-related risk factors and risk of severe influenza
- 2 outcomes in cancer survivors: a matched cohort study using linked
- 3 English electronic health records data
- 4
- 5 Helena Carreira*,¹ Helen Strongman*,¹ Maria Peppa,^{2,3} Helen I McDonald,^{2,3}
- 6 Isabel dos-Santos-Silva,¹ Susannah Stanway,⁴ Liam Smeeth,¹ Krishnan
- 7 Bhaskaran¹
- 8 (*equal contribution)
- 9
- 10 ¹ Department of Non-communicable Disease Epidemiology, London School of Hygiene and
- 11 Tropical Medicine, United Kingdom
- 12 ² Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical
- 13 Medicine, United Kingdom
- 14 ³NIHR Health Protection Research Unit in Immunisation, United Kingdom
- ⁴ Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey,
- 16 United Kingdom.
- 17

18

19

20 Correspondence to:

- 21 Helena Carreira, London School of Hygiene & Tropical Medicine.
- 22 Keppel Street, WC1 7HT London, UK; <u>Helena.carreira@lshtm.ac.uk</u>
- 23
- 24
- 25
- Abstract: 247 words
- 27 Manuscript: 3554 words

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 Abstract

2 Background

3 People with active cancer are recognised as at risk of COVID-19 complications, but it

- 4 is unclear whether the much larger population of cancer survivors is at elevated risk.
- 5 We aimed to address this by comparing cancer survivors and cancer-free controls for
- 6 (i) prevalence of comorbidities considered risk factors for COVID-19; and (ii) risk of
- 7 severe influenza, as a marker of susceptibility to severe outcomes from epidemic
- 8 respiratory viruses.

9 Methods

We included survivors (≥1 year) of the 20 most common cancers, and age, sex and general practice-matched cancer-free controls, derived from UK primary care data linked to cancer registrations, hospital admissions and death registrations. Comorbidity prevalences were calculated 1 and 5 years from cancer diagnosis. Risk of hospitalisation or death due to influenza was compared using Cox models adjusted for baseline demographics and comorbidities.

16 Findings

17 108,215 cancer survivors and 523,541 cancer-free controls were included. Cancer 18 survivors had more asthma, other respiratory, cardiac, diabetes, neurological, renal, 19 and liver disease, and less obesity, compared with controls, but there was variation by 20 cancer site. There were 205 influenza hospitalisations/deaths, with cancer survivors at 21 higher risk than controls (adjusted HR 2.78, 95% CI 2.04-3.80). Haematological cancer 22 survivors had large elevated risks persisting for >10 years (HR overall 15.17, 7.84-23 29.35: HR >10 years from cancer diagnosis 10.06, 2.47-40.93). Survivors of other 24 cancers had evidence of raised risk up to 5 years from cancer diagnosis only (HR 2.22, 25 1.31-3.74).

26 Interpretation

27 Risks of severe COVID-19 outcomes are likely to be elevated in cancer survivors. This

- should be taken into account in policies targeted at clinical risk groups, and vaccination
 for both influenza, and, when available, COVID-19, should be encouraged in cancer
- 30 survivors.
- 31

32 Funding

- 33 Wellcome Trust, Royal Society, NIHR.
- 34

1 2	Research in context
3	Evidence before this study
4	Few data are available to date on how COVID-19 affects cancer survivors. We
5	searched PubMed with the keywords "influenza cancer survivors" to identify studies
6	that compared severe influenza outcomes in cancer survivors and in a control group.
7	No study was identified.
8	
9	Added value of this study
10	In this matched cohort study of routinely collected electronic health records, we
11	demonstrated raised risks of influenza hospitalisation or mortality in survivors from
12	haematological malignancies for >10 years after diagnosis, and in survivors from
13	solid cancers up to 5 years after diagnosis.
14	
15	Implications of all the available evidence
16	Cancer survivorship appears to be an important risk factor for severe influenza
17	outcomes, suggesting that cancer survivors may also be at raised risk of poor
18	COVID-19 outcomes. This should be taken into account in public health policies
19	targeted at protecting clinical risk groups. Influenza vaccination should be
20	encouraged in this group, and may need to be extended to a wider population of
21	medium- to long-term cancer survivors than currently recommended.
22	

Introduction 1

2 As of 7 July 2020, the novel Coronavirus disease 2019 (COVID-19) has been 3 diagnosed in over 11.6 million individuals with more than 539,000 deaths reported 4 worldwide.¹ Around 20% of individuals contracting the virus are estimated to develop 5 severe disease requiring hospitalisation, with a high risk of mortality.² A key aspect of 6 managing the impacts of the pandemic is understanding who is vulnerable to 7 experiencing severe outcomes, so that mitigation strategies can be targeted at those 8 most in need. Those under current treatment for cancer were recognised early on as being a high risk group,³ but the extent to which the much larger population of medium-9 10 to long-term cancer survivors, might be considered vulnerable is unknown. In England 11 alone, this group includes over 1.8 million people.⁴

12 Current guidance on who should be considered vulnerable has been largely based on 13 policies developed for previous epidemic respiratory viruses, notably influenza. For 14 example, vaccination against influenza is only recommend for individuals under active 15 treatment for cancer and for up two years following some treatments and 16 haematological cancers,⁵ while longer-term cancer survivors with no recent 17 immunosuppressing treatment are not considered high-risk in vaccination guidance 18 from Public Health England or the American Cancer Society.^{5,6} Yet medium- to long-19 term cancer survivors could plausibly be at raised risk of severe COVID-19 outcomes. 20 Studies among women with breast cancer have found chemotherapy to be associated 21 with changes in immune parameters that did not return to pre-treatment levels a year 22 or more after end of treatment, raising the possibility of a long-term weakened immune system in cancer survivors.^{7,8} In addition, cancer survivors have known raised risks of 23 24 heart disease,⁹ which is itself an emerging risk factor for COVID-19 mortality.¹⁰ One 25 large UK study identified raised risks of COVID-19 mortality in survivors of 26 haematological malignancies even several years after cancer diagnosis,¹¹ but there is 27 little other evidence to date to inform policy around managing COVID-19 related risks 28 in cancer survivors.

29 We therefore aimed to investigate whether cancer survivors are likely to be a high-risk 30 group for severe outcomes during the current COVID-19 pandemic in two ways: first, 31 by comparing the prevalence of risk factors currently used to guide COVID-19 policy 32 between site-specific cancers survivors and cancer free controls; second, by 33 comparing the risk of influenza hospitalisation or death between cancer survivors and 34 cancer free controls, as a way of exploring susceptibility to severe outcomes from 35 epidemic respiratory viruses.

1 Methods

- 2 This study is reported as per the Strengthening the Reporting of Observational
- 3 Studies in Epidemiology (STROBE) guideline (S1 Checklist).
- 4

5 Study design and data sources

6 We carried out a population-based cohort study among 1-year survivors of the 20 most 7 common site-specific cancers matched to cancer-free controls. We used primary care 8 data from Clinical Practice Research Datalink (CPRD GOLD)¹² linked to national data 9 on hospital admissions from the Hospital Episode Statistics Admitted Patient Care 10 (HES APC) database,¹³ cancer registrations from the National Cancer Registration and 11 Analysis Service (NCRAS),¹⁴ death registrations – including cause of death information 12 - from the Office of National Statistics mortality database, and postcode-based index 13 of Multiple Deprivation data.⁹ CPRD GOLD comprises routinely collected clinical and 14 administrative data from general practices in the UK that use Vision software and have 15 chosen to participate; approximately 7% of the UK population is included. Data include 16 Read-coded diagnoses and care events, drug prescriptions, numerical measurements 17 (e.g., height and weight), laboratory test results (e.g. serum creatinine) and health risk 18 factors (e.g. smoking status). Secondary care diagnoses reported to the general 19 practitioner (GP) through discharge letters are typically recorded in the general 20 practice record if they are considered to affect the ongoing care of the patient. Linked 21 International Classification of Diseases, version 10 (ICD-10) coded HES APC and 22 NCRAS data improve ascertainment of diseases treated in secondary care.⁹ Use of 23 linked data restricted our study to England and the study period covered by all linked 24 data sources, January 1 1990 to December 31 2015.

25

26 Study population

27 Cohorts of adult cancer survivors (aged ≥18 years) were identified for each of the 20 28 most common cancer sites (listed in Table 1), as in a previous study.⁹ Briefly, we used 29 CPRD GOLD, HES APC, and NCRAS to identify 1-year survivors of incident cancer 30 diagnoses. Incident diagnoses were defined as the earliest record of a malignant 31 cancer of interest among individuals with at least 1 year of follow-up meeting CPRD 32 internal quality control criteria prior to the diagnosis (to ensure that the cancer was 33 incident). The derivation of the final analysis cohort is described in Supplementary 34 Figure S1. Cancer survivors with missing data on smoking (5.5%), body mass index 35 (13.0%), or index of multiple deprivation (an area-based proxy for socioeconomic 36 status derived from the patient's postcode; <0.1%) were excluded from the cohorts.

1 Older records were more likely to be excluded, as completeness of lifestyle information 2 improved when the Quality and Outcomes Framework was introduced in 2004.¹² 3 Cancer survivors were followed up from 1 year after diagnosis (index date) and 4 matched on age (±3 years), sex, and general practice to 5 controls with no history of 5 cancer and at least 2 years of follow-up prior to the index date of the matched cancer 6 survivor (since cancer survivors had to have one year of follow-up before and after the 7 date of cancer diagnosis to be included). Cancer survivors were eligible to be selected 8 as controls until the date of the incident cancer.

9

10 Outcome and covariates

The main outcome for the study was influenza hospitalisation or death, identified using ICD-10 codes in HES and ICD-9 and ICD-10 codes in ONS mortality data (codes available in Supplementary Table S1). For the primary analysis, we counted hospitalisations with a primary diagnosis of influenza, and deaths with an underlying cause of influenza. In a sensitivity analysis, we broadened the definition to include hospitalisations/deaths with any code for influenza present.

17 Age and sex were matching factors. Other covariates were index of multiple 18 deprivation quintile, smoking status (never, former, current smoker), and common 19 comorbidities identified a priori as of potential importance in determining risk of severe 20 COVID-19 outcomes, namely asthma, chronic respiratory disease other than asthma, 21 chronic heart disease, chronic liver disease, chronic neurological disease, chronic 22 kidney disease, diabetes, obesity, sickle cell disease or splenectomy. Other causes of 23 immunosuppression were not included due to overlap with cancer and its treatment. In 24 a secondary analysis we also described the total number of comorbidities (0 vs 1 vs 25 ≥2 comorbidities from the aforementioned list). Full variable definitions and code lists 26 are provided in Supplementary Table S1.

27

28 Statistical analysis

29 Prevalence of COVID-19 related risk factors in cancer survivors and controls: Among 30 cancer survivors and controls alive and under follow-up in CPRD GOLD at the index 31 date (i.e. 1 year after cancer diagnosis for cancer survivors) and 4 years later (5 years 32 after diagnosis), we calculated the proportion with each morbidity of interest for all 33 cancers combined and individual cancer sites. The numerator included those with any 34 history of the relevant comorbidity at the given time point, except for obesity, which 35 was classified based on the most recent body mass index (BMI) measure available at 36 that time point.

1 Risk of influenza hospitalisation and mortality in cancer survivors and controls: 2 Individuals were followed up from the index date until the earliest occurrence of the 3 outcome, death without the outcome, or end of study period. Follow-up was not 4 censored at the end of data collection in CPRD GOLD because the main analysis did 5 not require post-baseline primary care data. We then fitted Cox proportional hazards 6 models with time since index date as the timescale, initially accounting only for 7 matching factors (i.e. age at index date, sex, and general practice) through stratification 8 by matched set and then additionally adjusting for the presence of risk factors at the 9 index date (for this analysis obesity was classified at the cancer diagnosis date since 10 weight measures in the year following cancer diagnosis may be unstable). We 11 examined the role of time since cancer diagnosis, by fitting a time-updated variable 12 indicating time of cancer survivorship (1 to <5, 5 to <10, and ≥ 10 years since diagnosis, 13 vs control group patient).

14 Since haematological malignancies directly affect the immune system and treatments 15 may have long-term immune consequences, we stratified results by haematological 16 versus other cancers by fitting a three-level cancer survivorship variable. Due to limited power, we did not break cancer sites down further. In a post hoc analysis, the exposure 17 18 variable included each haematological malignancy separately (leukaemia, non-19 Hodgkin lymphoma, multiple myeloma) and four groups of solid cancers (i.e. breast, 20 gastrointestinal, genitourinary, others); Wald tests were used after model estimation to 21 test the null hypothesis of heterogeneity of effect among subgroups.

As a secondary analysis, we explored mediation of any raised risk of the primary outcome by development of recognised risk factors during follow-up, by adjusting for time-updated risk factor variables (taking the value "0" until the risk factor is first present, and "1" afterwards). This analysis was additionally censored at the end of follow-up in CPRD GOLD, since it relies on post-baseline primary care data.

27 Patients with missing data on BMI, smoking or deprivation were excluded from the 28 cohorts (see above), therefore all models were based on complete case analyses. 29 Multiple imputation was not used, as the missingness was considered likely to be not 30 at random in the primary care setting ^{15,16}, and complete case analysis minimises bias 31 in this situation, providing missingness is conditionally independent of the outcome 32 ¹⁷.Sensitivity analyses: We conducted two main sensitivity analyses. First, we 33 broadened our definition of the outcome to include influenza recorded anywhere in the 34 hospitalisation or death record, to account for the possibility of differential prioritisation 35 of influenza codes between cancer survivors and controls. Second, we adjusted for 36 time-updated influenza vaccination status and ever receipt of a pneumococcal vaccine, 37 as cancer survivors may be more likely to receive influenza and pneumococcal 38 vaccinations than general population controls due to higher engagement with

1 healthcare, or vaccination indicated by immunosuppression following cancer and its 2 treatment, which may protect against influenza and influenza-related death from 3 secondary bacterial pneumonia. Influenza vaccinations were considered current from 4 the date of vaccination until the start of the following influenza season in September. 5 As vaccination records were ascertained from primary care data, these analyses were 6 additionally censored at the end of CPRD follow up; we also re-ran the primary model 7 with this additional censoring in order to provide a similarly censored comparator for 8 the sensitivity and mediation analysis models.

9 *Ethics:* This study was approved by the London School of Hygiene & Tropical Medicine

10 Ethics Committee (LSHTM Ethics Ref: 22416) and the Independent Scientific Advisory

11 Committee for the Medicines and Healthcare products Regulatory Agency database

12 research (20_082). Individual consent was not required for this study. CPRD supplies

13 anonymised data for public health research; individuals are free to opt-out from having

14 their data included in the database.

15 Role of funding source: The study funders had no role in study design; in the

16 collection, analysis, and interpretation of data; and in the writing of the article.

1 Results

2 This study included 108,215 cancer survivors, of which 9,685 had prior haematological

- 3 malignancies, and 523,541 individuals with no history of cancer (Table 1). Median
- 4 (interquartile range [IQR]) age was 67 (58, 76) in the cancer survivor and comparison
- 5 group; 6,674 (52.4%) and 277,781 (53.1%) of subjects were female, respectively.
- 6 Prevalence of COVID-19 related risk factors in cancer survivors and controls

7 For all cancers combined, we observed higher absolute prevalence of all risk factors 8 for severe COVID-19 except for obesity and sickle cell disease/splenectomy in 1-year 9 cancer survivors, compared to the cancer-free comparison group (Figure 1, sickle 10 cell/splenectomy not shown as the prevalence was <0.2% in all groups). At 5-years 11 after diagnosis, cancer survivors overall had slightly higher prevalence of all risk factors 12 except heart disease and neurological conditions (differences in prevalences ranging 13 from 0.3% for diabetes and chronic liver disease, to 1.8% for chronic kidney disease). 14 Survivors of most site-specific cancers also had raised prevalences of these risk 15 factors, with the magnitude varying by cancer site. The prevalence of obesity was lower 16 in cancer survivors than controls for several cancer sites, but was substantially more 17 common in survivors of uterus and kidney cancers (prevalence difference at 5 years 18 20.1% [95%CI 19.8-20.5], and 8.5% [95%CI 8.1-8.8], respectively). Overall, 62.7% of 19 the cancer survivors had at least 1 of the included comorbidities 5 years after 20 diagnosis, while 37.3% had two or more (Supplementary Table S2). Comorbidity 21 prevalences stratified by age and sex are provided in Supplementary Figure S2(a)-(h).

22 Risk of influenza hospitalisation and mortality in cancer survivors and controls

23 205 people had the primary outcome (190 hospitalisations, 15 deaths) during a median 24 follow-up time from the index date of 4.7 years in cancer survivors (IQR 1.9-8.4 years) 25 and 6.2 years in controls (IQR 3.3-9.9 years); follow-up exceeded 10 years for 19,273 26 (18%) cancer survivors and 128,132 (25%) controls. The risk of influenza 27 hospitalization or death was 2.7 times higher (95%CI 2.12-3.44) in cancer survivors 28 compared to people with no history of cancer after accounting for matching factors only 29 (Table 2). Control for other covariates had little impact on the relative risk estimate 30 (adjusted HR=2.78; 95%CI 2.04-3.80).

31 Stratification by cancer group (haematological vs non-haematological) showed 32 substantial differences. Haematological cancer survivors had 15 times higher risk of a 33 severe influenza outcome compared to people without cancer (adjusted HR 15.17; 34 95%CI 7.84-29.35), and further stratifying by time since cancer diagnosis, the hazard 35 ratio was 29.56 (95%Cl 10.20-85.66) for those 1 to <5 years from diagnosis, falling to 36 9.56 (95%CI 4.39-20.84) and 10.06 (95%CI 2.47-40.93) for those 5 to <10, and 10+

1 years from diagnosis respectively. Associations were smaller for non-haematological 2 cancer survivors. The overall adjusted HR was 1.38 but compatible with chance 3 variation (95%CI 0.92-2.07). However, stratification by time since diagnosis suggested 4 a doubling of risk in those 1 to <5 years from diagnosis (adjusted HR 2.22, 1.31-3.74) 5 with no raised risk in longer-term survivors. 6

7 Sensitivity, mediation and post-hoc analyses

8 Using hospitalisations and deaths with any mention of influenza in the outcome 9 definition led to more events being included (n=320) but a very similar pattern of results 10 to the primary analysis (Supplementary Table S3). In analyses that censored at end of 11 CPRD follow-up, fewer events were included (n=167) but hazard ratios were generally 12 larger than in the primary analysis (overall adjusted HR for cancer survivors vs controls 13 3.88, 2.54-5.91, Supplementary Table S4). Additional control for time-updated 14 exposure to influenza and pneumococcal vaccination led to similar but slightly stronger 15 associations (overall HR 4.06, 2.65-6.24), while adjusting for mediators led to slightly 16 weaker associations (overall HR 3.27, 95%CI 2.12-5.04), but in both cases patterns of 17 results were similar. There was no strong statistical evidence of a variation in the HRs 18 among survivors of leukaemia, non-Hodgkin lymphoma and multiple myeloma 19 (p=0.08), or among survivors from the different solid cancers (p=0.42).

1 Discussion

Most comorbidities thought to be risk factors for COVID-19 were more prevalent in cancer survivors than cancer-free controls, with variation by cancer site. After accounting for baseline demographics, deprivation, smoking and risk factors distribution, the risks of influenza hospitalisation and death were elevated >9-fold in haematological cancer survivors compared with matched controls for at least 10 years after diagnosis, and >2-fold in non-haematological cancer survivors in the one to five years after diagnosis.

9 To our knowledge, this is the first large cohort study using prospectively collected data 10 to quantify the relative risk of severe influenza outcomes in different groups of cancer 11 survivors compared to the general population, including stratification by time since 12 diagnosis. The few previous studies in this area have reported high rates of influenza 13 among cancer survivors, consistent with our findings, but have lacked a cancer-free 14 comparison group.¹⁸⁻²¹ Hermann et al. investigated outcomes among patients with a 15 history of cancer presenting with influenza, and found no difference in mortality 16 according to haematological or non-haematological cancer type, or activity of the 17 cancer.¹⁸ Our results showed considerably higher risks of hospitalisation or death 18 among haematological cancer survivors, which could be consistent with the findings in 19 Hermann et al. if haematological cancer survivors are at increased risk of infection, but 20 not mortality once infected, compared to non-haematological cancer survivors. Other 21 studies have investigated vulnerability to influenza infection of any severity; two studies 22 using administrative claims data in South Korea found a high rate of claims for 23 influenza among both breast cancer survivors and survivors of childhood cancers.^{19,20} 24 Similarly, Australian survey data found that a large proportion (38%) of hematopoietic 25 stem cell transplant survivors had had influenza-like illnesses in the time (median 5 26 years) since their transplant suggesting potentially high vulnerability to infection, but there was no control group or information on severity of infection.²¹ 27

28 Direct evidence on how COVID-19 affects cancer patients and survivors is immature. 29 Early evidence from China and Italy suggested that patients with history of cancer were 30 overrepresented among those admitted to hospital with COVID-19.^{22,23} The large UK 31 OpenSAFELY study found substantially raised risks of COVID-19 mortality among 32 individuals with prior haematological cancer persisting for at least 5 years from cancer 33 diagnosis, and smaller raised risks for those with a history of non-haematological 34 cancers up to 5 years from diagnosis, consistent with our findings for influenza.¹¹ A 35 study from the COVID-19 and Cancer Consortium (CCC19) reported high 30-day 36 mortality among individuals with laboratory-confirmed COVID-19 and active or

1 previous malignancy, finding high 30-day mortality, even among those in remission, 2 though active disease was a strong predictor of mortality.²⁴ Finally, a study that 3 focussed on patients with active cancer and COVID-19 found a non-statistically 4 significant increased risk of mortality in patients exposed to chemotherapy 4 weeks 5 prior to infection (OR=1.18, 95%CI 0.81-1.72), compared to cancer patients that did 6 not receive chemotherapy, but the small numbers involved require further studies to 7 confirm these associations.²⁵

8 We used a large cohort of cancer survivors and matched controls, nearly a guarter of 9 whom were followed up for more than 10 years. The size of our study enabled us to 10 estimate prevalence of risk factors for severe respiratory infections in site-specific 11 cancer survivors for the twenty most common cancer sites with good precision, and to 12 adjust our primary analysis of severe influenza outcomes for multiple risk factors and 13 stratify by type of cancer (haematological vs other). Multiple validation studies have 14 demonstrated the validity of CPRD primary care data for measuring disease 15 phenotypes including cancer, especially when combined with additional linked data 16 sources.²⁶ Our primary analysis was designed to be specific to hospitalisations and 17 deaths caused by influenza, and a broader definition in sensitivity analysis found 18 similar results. A second sensitivity analysis took account of time-updated vaccination 19 status, which showed that the associations we observed persisted, and in fact were 20 stronger after accounting for this apparent negative confounder.

21 There are some important limitations. We analysed severe influenza in an attempt to 22 inform COVID-19 policy but despite both being infectious respiratory illnesses, it is not 23 certain that risk factors for severe influenza will have the same associations with 24 COVID-19. Our approach follows that of policy makers who have assumed parallels 25 with influenza in the absence of mature COVID-19 data.²⁷ As data from the COVID-19 26 pandemic itself have started to flow, they have largely confirmed a broad overlap 27 between those at high risk for seasonal influenza and for severe COVID-19 28 outcomes.¹¹ Another limitation was that we did not have data on anti-cancer 29 treatments, so could not separate cancer survivors into those under active treatment 30 or not undergoing any treatment, which may be an important determinant of risk. We 31 only included cancer survivors at least one year out from diagnosis, so it is likely that 32 most patients with high-grade malignancies would have completed primary treatment, 33 but people with low-grade tumours could conceivably have received anticancer 34 therapies some years after initial diagnosis, which could explain part of the medium-35 to long-term increased risk of severe influenza; linked cancer treatment data will be 36 needed to investigate this further. We cannot rule out that differences in the prevalence 37 of risk factors between cancer survivors and controls five years post-diagnosis may be

1 due to increased contact with health services, particularly for diseases such as chronic 2 kidney disease which may be asymptomatic. Our primary outcome combined influenza 3 hospitalisations and deaths but was dominated by the former; it is plausible that there 4 may be a lower threshold for hospitalisation in cancer survivors which could have 5 exaggerated the difference in risk of the primary outcome between cancer survivors 6 and controls, but is unlikely to fully explain the large associations we observed. Finally, 7 we had some missing data on smoking and BMI data, and we excluded those with 8 missing data from the analysis; this is unlikely to affect our findings under the 9 assumption that the association between cancer survivorship and severe respiratory 10 outcomes is the same in people with and without missing data, conditional on the 11 covariates included in the model. We have no reason to doubt this assumption, as 12 recording of BMI and smoking in primary care could be associated with cancer 13 survivorship but most likely is not associated with the risk of influenza hospitalization 14 or death.

15 The high prevalence of several established COVID-19 risk factors in cancer survivors, 16 and the increased risk of influenza hospitalisation and death in survivors of 17 haematological cancers even many years from diagnosis, and in survivors from other 18 cancers in the first five years of survivorship, indicate a likely increased risk of severe 19 COVID-19 outcomes in these patient groups. Early direct evidence from the COVID-20 19 pandemic appears to be consistent with this. These findings suggest that cancer 21 survivorship should be considered a potentially important risk factor for severe COVID-22 19 outcomes in public health policy. At present, while UK policy defines those with 23 active cancers and/or receiving treatments as high-risk for COVID-19 complications, 24 the much larger overall population of cancer survivors does not appear in either 25 moderate or high-risk groupings;²⁸ these risk groupings become increasingly important 26 as general population social distancing measures are eased and advice becomes 27 more targeted to those at risk.

28 Our results also have implications for preventive medicine in the coming autumn and 29 winter, when influenza and SARS-CoV-2 are expected to coexist in the population. 30 Improving influenza vaccination coverage among cancer survivors should be a priority, as the vaccine is both effective and safe^{29,30} but coverage has been reported in the 31 32 range of 50% to 76% among cancer survivors in the US and in the UK.^{31,32} 33 Immunisation for streptococcus pneumoniae may also be considered.³³ Of note, UK 34 influenza vaccine guidance focusses on cancer patients with active or recent disease 35 or treatment;⁵ our findings suggest that a broader population of cancer survivors should 36 be considered as a high-risk group for influenza vaccination.

1 Future studies should focus on the risk of severe COVID-19 in cancer survivors,

2 explore the role of comorbidities and prior exposure to specific anti-cancer therapies,

3 disaggregating data by cancer site when possible.

4 In conclusion, survivors of haematological malignancies had substantially elevated 5 risks of influenza hospitalisation or death persisting for at least 10 years after cancer 6 diagnosis, while risk was doubled for survivors of other cancers for up to 5 years from 7 diagnosis. In addition, cancer survivors had higher prevalence of several chronic 8 conditions associated with severe COVID-19, compared to people with no history of 9 cancer. This should be taken into account in public health policies targeted at 10 protecting clinical risk groups. Influenza vaccination should be encouraged in this 11 group, and may need to be extended to a wider population of medium- to long-term 12 cancer survivors than currently recommended.

1 Declaration of Interests

- 2 Dr. McDonald reports grants from NIHR Health Protection Research Unit in
- 3 Immunisation, during the conduct of the study; Dr. Stanway reports personal fees
- 4 from Roche, personal fees from Eli Lilly, personal fees from Novartis, outside
- 5 submitted work; Dr. Bhaskaran reports grants from Wellcome Trust, grants from
- 6 Royal Society, during the conduct of the study; all other authors have no conflicts of
- 7 interest to disclose.
- 8

9 Funding

- 10 This work was supported by the National Institute for Health Research (NIHR) Health
- 11 Protection Research Unit (HPRU) in Immunisation; and the Wellcome Trust and
- 12 Royal Society (grant no. 107731/Z/15/Z).
- 13

14 Data sharing

This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The terms of our licence to access the data preclude us from sharing individual patient data with third parties. The raw data may be requested directly from CPRD following their usual procedures.

20

21 Acknowledgements

This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the author/s alone. The study was approved by the Independent Scientific Advisory Committee (approval number: 20_082).

28

29 **Contributors**

30 KB, HS and HC designed the study. HS and KB created the data set for a previous

- 31 $\,$ study. MP and HMcD created code lists to identify immunisations in the primary care
- 32 data. HC, HS and KB conducted the analyses in the present study. HC and HS wrote
- 33 the first draft of the manuscript. All authors revised the manuscript for important
- 34 intellectual content. HC, HS and KB are guarantors for this study, had access to all
- 35 study data and accept full responsibility for the work.

1 References

2	1. Johns Hopkins Coronavirus Resource Centre. COVID-19 Map. 2020.
3	https://coronavirus.jhu.edu/map.html (accessed May 2020).
4	2. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19.
5	Lancet 2020; 395 (10229): 1014-5. doi: 10.1016/S0140-6736(20)30633-4.
6	3. Public Health England. Guidance on shielding and protecting people defined
7	on medical grounds as extremely vulnerable from COVID-19. 2020.
8	https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-
9	extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-
10	extremely-vulnerable-persons-from-covid-19 (accessed May 2020).
11	4. Macmillan Cancer Support and Public Health England's National Cancer
12	Registration and Analysis Service. UK complete cancer prevalence for 2013. Version
13	2.0a April 2017. http://www.ncin.org.uk/about_ncin/segmentation2020).
14	5. Public Health England. Influenza - the green book (chapter 19). In: Ramsay
15	M, ed. Immunisation against infectious disease; 2019.
16	6. American Cancer Society. Vaccinations and Flu Shots for People with
17	Cancer. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-
18	effects/low-blood-counts/infections/vaccination-during-cancer-treatment.html
19	(accessed June 2020).
20	7. Mozaffari F, Lindemalm C, Choudhury A, Granstam-Bjorneklett H, Lekander
21	M, Nilsson B, Ojutkangas ML, Osterborg A, Bergkvist L, Mellstedt H. Systemic
22	immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and
23	cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study. Cancer
24	Immunol Immunother 2009; 58 (1): 111-20. doi: 10.1007/s00262-008-0530-5.
25	8. Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA,
26	Carter CR. Lymphocyte depletion and repopulation after chemotherapy for primary
27	breast cancer. Breast Cancer Res 2016; 18 (1): 10. doi: 10.1186/s13058-015-0669-x.
28	9. Padmanabhan S, Carty L, Cameron E, Ghosh RE, Williams R, Strongman H.
29	Approach to record linkage of primary care data from Clinical Practice Research
30	Datalink to other health-related patient data: overview and implications. Eur J
31	<i>Epidemiol</i> 2019; 34 (1): 91-9. doi: 10.1007/s10654-018-0442-4.
32	10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X,
33	Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and
34	risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
35	retrospective cohort study. Lancet 2020; 395 (10229): 1054-62. doi: 10.1016/S0140-
36	6736(20)30566-3.
37	11. Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis
38	HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, Mcdonald HI, MacKenna B,

Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong A, Grieve R, Harrison D,
 Forbes H, Schultze A, Croker RT, Parry J, Hester F, Harper S, Perera R, Evans S,

3 Smeeth L, Goldacre B. OpenSAFELY: factors associated with COVID-19 death in 17

4 million patients. *Nature* 2020. doi: 10.1038/s41586-020-2521-4.

5 12. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T,

6 Smeeth L. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J

7 *Epidemiol* 2015; **44**(3): 827-36. doi: 10.1093/ije/dyv098.

8 13. Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data Resource

9 Profile: Hospital Episode Statistics Admitted Patient Care (HES APC). Int J Epidemiol

10 2017; **46**(4): 1093-i. doi: 10.1093/ije/dyx015.

11 14. Henson KE, Elliss-Brookes L, Coupland VH, Payne E, Vernon S, Rous B,

12 Rashbass J. Data Resource Profile: National Cancer Registration Dataset in

13 England. Int J Epidemiol 2020; **49**(1): 16-h. doi: 10.1093/ije/dyz076.

14 15. Bhaskaran K, Forbes HJ, Douglas I, Leon DA, Smeeth L. Representativeness

15 and optimal use of body mass index (BMI) in the UK Clinical Practice Research

16 Datalink (CPRD). *BMJ Open* 2013; **3**(9): e003389. doi: 10.1136/bmjopen-201317 003389.

18 16. Bhaskaran K, Smeeth L. What is the difference between missing completely

19 at random and missing at random? *Int J Epidemiol* 2014; **43**(4): 1336-9. doi:

20 10.1093/ije/dyu080.

21 17. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with
22 complete-case analysis for missing covariate values. *Stat Med* 2010; **29**(28): 292023 31. doi: 10.1002/sim.3944.

18. Hermann B, Lehners N, Brodhun M, Boden K, Hochhaus A, Kochanek M,
Meckel K, Mayer K, Rachow T, Rieger C, Schalk E, Weber T, Schmeier-Jurchott A,
Schlattmann P, Teschner D, von Lilienfeld-Toal M. Influenza virus infections in

27 patients with malignancies - characteristics and outcome of the season 2014/15. A

28 survey conducted by the Infectious Diseases Working Party (AGIHO) of the German

29 Society of Haematology and Medical Oncology (DGHO). *Eur J Clin Microbiol* 2017;

30 **36**(3): 565-73. doi: 10.1007/s10096-016-2833-3.

Heo J, Chun M, Oh YT, Noh OK, Kim L. Influenza Among Breast Cancer
Survivors in South Korea: A Nationwide Population-Based Study. *In vivo (Athens, Greece)* 2017; **31**(5): 967-72. doi: 10.21873/invivo.11155.

Heo J, Jung HJ, Noh OK, Kim L, Park JE. Incidence of Influenza Among
Childhood Cancer Survivors in South Korea: A Population-based Retrospective
Analysis. *In vivo (Athens, Greece)* 2020; **34**(2): 929-33. doi: 10.21873/invivo.11860.

21. Dyer G, Gilroy N, Brice L, Kabir M, Gottlieb D, Huang G, Hogg M, Brown L,

38 Greenwood M, Larsen SR, Moore J, Hertzberg M, Tan J, Ward C, Kerridge I. A

39 survey of infectious diseases and vaccination uptake in long-term hematopoietic

1 stem cell transplant survivors in Australia. Transplant infectious disease : an official 2 journal of the Transplantation Society 2019; **21**(2): e13043. doi: 10.1111/tid.13043. 3 22. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li 4 S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. 5 Lancet Oncol 2020; 21(3): 335-7. doi: 10.1016/S1470-2045(20)30096-6. 6 23. Trapani D, Marra A, Curigliano G. The experience on coronavirus disease 7 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. Eur J 8 Cancer 2020; 132: 199-206. doi: 10.1016/j.ejca.2020.04.017. 9 24. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, 10 Shete S, Hsu CY, Desai A, de Lima Lopes G, Jr., Grivas P, Painter CA, Peters S, 11 Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya 12 MB. Castellano D. Del Prete SA. Doroshow DB. Egan PC. Elkrief A. Farmakiotis D. 13 Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, 14 Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, 15 Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou 16 OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt 17 A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, 18 Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou 19 AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, Covid, Cancer C. Clinical 20 impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020. 21 doi: 10.1016/S0140-6736(20)31187-9. 22 Lee LYW, Cazier JB, Starkey T, Turnbull CD, Team UKCCMP, Kerr R, 25. 23 Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other 24 anticancer treatments: a prospective cohort study. Lancet 2020. doi: 10.1016/S0140-25 6736(20)31173-9. 26 Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and 26. 27 validity of diagnoses in the General Practice Research Database: a systematic 28 review. British journal of clinical pharmacology 2010; 69(1): 4-14. doi: 29 10.1111/j.1365-2125.2009.03537.x. 30 27. Scientific Advisory Group for Emergencies (UK). Second SAGE meeting on 31 Wuhan Coronavirus - 28 January 2020. 32 https://www.gov.uk/government/publications/sage-minutes-coronavirus-covid-19-33 response-28-january-2020 (accessed June 2020). 34 28. NHS Digital. Coronavirus (COVID-19): Shielded patients list. 2020. 35 https://digital.nhs.uk/coronavirus/shielded-patient-list (accessed June 2020). 36 29. Blanchette PS, Chung H, Pritchard KI, Earle CC, Campitelli MA, Buchan SA, 37 Schwartz KL, Crowcroft NS, Gubbay JB, Karnauchow T, Katz K, McGeer AJ, 38 McNally JD, Richardson DC, Richardson SE, Rosella LC, Simor A, Smieja M, 39 Zahariadis G, Campigotto A, Kwong JC. Influenza Vaccine Effectiveness Among

- 1 Patients With Cancer: A Population-Based Study Using Health Administrative and
- 2 Laboratory Testing Data From Ontario, Canada. J Clin Oncol 2019; 37(30): 2795-
- 3 804. doi: 10.1200/JCO.19.00354.
- 4 30. Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici
- 5 L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane
- 6 Database Syst Rev 2018; 2: CD008983. doi: 10.1002/14651858.CD008983.pub3.
- 7 31. Khan NF, Carpenter L, Watson E, Rose PW. Cancer screening and
- 8 preventative care among long-term cancer survivors in the United Kingdom. Br J
- 9 Cancer 2010; 102(7): 1085-90. doi: 10.1038/sj.bjc.6605609.
- 10 32. Stafford KA, Sorkin JD, Steinberger EK. Influenza vaccination among cancer
- 11 survivors: disparities in prevalence between blacks and whites. J Cancer Surviv
- 12 2013; 7(2): 183-90. doi: 10.1007/s11764-012-0257-3.
- 13 33. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M,
- 14 Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I, Infectious Diseases
- 15 Society of A. 2013 IDSA clinical practice guideline for vaccination of the
- 16 immunocompromised host. Clin Infect Dis 2014; 58(3): 309-18. doi:
- 17 10.1093/cid/cit816.
- 18

1 List of tables

- 2 Table 1. Characteristics of the patients included in analyses.
- 3 Table 2. Relative risk of influenza hospitalisation or death in cancer survivors
- 4 compared to non-cancer controls.
- 5

6 List of figures

- 7 Figure 1. Prevalence of factors currently recognised as associated with high risk for
- 8 severe COVID-19 outcomes in cancer survivors and controls at 1 and 5 years after
- 9 diagnosis. Sickle cell disease and splenectomy are not presented due to the rarity of
- 10 the outcome.
- 11

12 Supplementary Materials

- 13 Supplementary table S1. Definition of the study variables.
- Supplementary table S2. Number of comorbidities at 1 and 5 years after cancerdiagnosis.
- 16 Supplementary table S3. Results from sensitivity analysis additionally including
- 17 outcomes where influenza was present but not considered the primary diagnosis in
- 18 the hospitalization, and/or the primary cause of death.
- 19 Supplementary table S4. Results from sensitivity and mediation analyses showing
- 20 the relative risk of influenza hospitalisation or death in cancer survivors compared to
- 21 cancer-free controls.
- 22 Supplementary figure S1. Flow chart of people included in the study.
- 23 Supplementary figure S2. Prevalence of factors currently recognised as associated
- 24 with high risk for severe COVID-19 outcomes in cancer survivors and controls
- 25 stratified by age group and sex.

1 Table 1. Characteristics of the patients included in analyses.

	Cancer survivors	Comparison group
Number (%)	108,215 (100)	523,541 (100
Cancer site, N (%)		
Bladder	7,712 (7.13)	
Breast	25,633 (23.69)	
Cervix	1,209 (1.12)	
Central nervous system	906 (0.84)	
Colorectal	14,216 (13.14)	
Gastric	1,507 (1.39)	
Kidney	2,197 (2.03)	
Leukaemia	3,419 (2.03)	
Liver	554 (0.51)	
Lung	5,369 (4.96)	
Malignant melanoma	7,098 (6.56)	
Multiple myeloma	1,843 (1.70)	
Non-Hodgkin lymphoma	4,423 (4.09)	
Oesophagus	1,794 (1.66)	
Oral cavity	1,584 (1.46)	
Ovary	2,710 (2.50)	
Pancreas	864 (0.80)	
Prostate	20,709 (19.14)	
Thyroid	1,028 (0.95)	
Uterus	3,440 (3.18)	
Years from index date to end of follow-up	0,110 (0110)	
Mean (SD)	5.7 (4.7)	7.0 (4.7
Median (IQR)	4.7 (1.9, 8.4)	•
Range	0.0-24.2	
Total person-years included (thousands)	620.144	3666.84
Demographics	0201111	
Age at index date (years)		
Mean (SD)	66.1 (13.3)	66.0 (13.2
Median (IQR)	67.0 (58.0, 76.0)	
Age at index date (years)	07.0 (00.0, 70.0)	07.0 (00.0, 70.0
18-39	4,028 (3.7)	19,208 (3.7
40-59	27,029 (25.0)	
60-79	60,347 (55.8)	293,080 (56.0
>=80	16,811 (15.5)	•
Gender	10,011 (15.5)	80,204 (15.3
Men	51 511 (17 C)	245 760 (46 (
Women	51,541 (47.6)	245,760 (46.9
	56,674 (52.4)	277,781 (53. ⁻
IMD quintile	40.004 (47.0)	04 000 (40 (
1 (least deprived)	19,334 (17.9)	94,233 (18.0
2	21,439 (19.8)	103,694 (19.8
3	20,649 (19.1)	99,684 (19.0
4 5 (mart having))	23,114 (21.4)	•
5 (most deprived)	23,679 (21.9)	114,162 (21.8
Previous vaccination at index date		
Influenza	72,924 (67.4)	322,908 (61.7
Pneumococcal	48,953 (45.2)	224,496 (42.9

Table 2. Relative risk of influenza hospitalisation or death in cancer survivors compared to non-cancer controls.

	No. of individuals		PY at risk	Associations adjusted for matching factors only*		Associations adjusted for risk factors for severe COVID-19 outcomes, smoking and IMD †	
		No. events [#] (no. deaths)		HR	95% CI	HR	95% CI
No cancer history	523,541	205 (15)	3,666,849	Ref		Ref	
All cancer survivors	108,215	85 (6)	620,144	2.70	2.12 – 3.44	2.78	2.04 - 3.80
1-5 years since diagnosis	108,215	46 (2)	326,913	4.16	2.94 – 5.88	4.34	2.86 - 6.59
5-10 years since diagnosis	59,938	27 (3)	201,332	2.15	1.44 – 3.21	2.37	1.53 – 3.66
>10 years since diagnosis	24,111	12 (1)	91,899	1.38	0.74 – 2.56	1.37	0.74 – 2.52
By cancer group							
Haematological malignancies	9,685	40 (3)	52,573	12.94	7.47 – 22.44	15.17	7.84 – 29.35
1-5 years since diagnosis	9,685	20 (1)	29,072	22.21	8.34 – 59.17	29.56	10.20 – 85.66
5-10 years since diagnosis	5,131	15 (2)	16,608	8.62	4.00 – 18.58	9.56	4.39 – 20.84
>10 years since diagnosis	1,870	≤5 (0)	6,894	9.90	2.46 – 39.78	10.06	2.47 - 40.93
All other cancers	98,530	45 (3)	567,570	1.50	1.09 – 2.05	1.38	0.92 – 2.07
1-5 years since diagnosis	98,530	26 (1)	297,841	2.47	1.61 – 3.80	2.22	1.31 – 3.74
5-10 years since diagnosis	54,807	12 (1)	184,724	1.05	0.62 – 1.80	1.08	0.58 – 2.01
>10 years since diagnosis	22,241	7 (1)	85,005	0.77	0.34 – 1.73	0.74	0.34 – 1.61


[#] Hospitalisations or deaths with influenza as the primary diagnosis/underlying cause.

* Cancer survivors and non-cancer controls were matched on age (within a 3-year age range), sex and primary care practice.

† Model adjusted for risk factors for poor COVID-19 outcomes (i.e. asthma and other chronic respiratory diseases, chronic neurological diseases, chronic liver disease, chronic heart disease, chronic kidney disease, sickle cell disease or splenectomy, diabetes and obesity), smoking (former vs. current vs. never smokers), and quintiles of relative deprivation measured by patient-postcode linked Index of Multiple Deprivation.

HR = Hazards ratio; PY = person-years at risk; Ref = reference category.

Asthma



Chronic liver disease

Cancer site	e (ICD10)	Preva CS G		Difference	
Oral Cavity	•	3.7	0.6	3.1 (3.0-3.2)	
(C00-06)		2.0	0.6	1.4 (1.3-1.5)	
Oesophageal		1.7	0.6	1.2 (1.1-1.3)	
(C15)		0.6	0.6	-0.1 (-0.10.0)	
Stomach	0	1.7	0.6	1.1 (1.1-1.2)	
(C16)		1.7	0.6	1.1 (1.0-1.2)	
Colorectal	e	0.9	0.5	0.5 (0.4-0.5)	
(C18-C20)	e	0.9	0.5	0.4 (0.3-0.5)	
Liver	•	38.8	0.5	38.3 (38.0-38.6)	
(C22)		44.7	0.3	44.4 (44.0-44.7)	
Pancreas	ен	3.1	0.4	2.7 (2.6-2.8)	
(C25)	с—в	6.8	0.6	6.2 (6.0-6.4)	
Lung	•	1.2	0.5	0.7 (0.6-0.8)	
(C34)		1.7	0.6	1.1 (1.0-1.2)	
Mal melanoma	0	0.3	0.4	-0.1 (-0.10.1)	
(C43)		0.3	0.3	0.0 (-0.0-0.0)	
Breast	8	0.4	0.4	0.0 (-0.0-0.1)	
(C50)		0.4	0.5	-0.0 (-0.1-0.0)	
Cervix		0.9	0.3	0.6 (0.5-0.6)	
(C53)		1.0	0.3	0.7 (0.6-0.8)	
Uterus		0.5	0.4	0.0 (-0.0-0.1)	
(C54-55)		0.5	0.5	-0.0 (-0.1-0.0)	
Ovaries	0	0.4	0.3	<mark>0.0 (0.0-0.1)</mark>	
(C56)		0.4	0.5	-0.1 (-0.1-0.0)	
Prostate	0	0.4	0.5	-0.1 (-0.10.0)	
(C61)		0.5	0.5	-0.0 (-0.1-0.0)	
Kidney	a	1.1	0.5	0.6 (0.5-0.6)	
(C64)		1.1	0.4	0.7 (0.6-0.7)	
Bladder	0	0.6	0.4	0.2 (0.1-0.2)	
(C67)		0.7	0.6	0.1 (0.1-0.2)	
Brain/CNS	8	0.7	0.3	0.3 (0.3-0.4)	
(C71-72)		0.7	0.3	0.4 (0.3-0.4)	
Thyroid	0	0.8	0.2	0.6 (0.5-0.6)	
(C73)		0.6	0.5	0.1 (0.0-0.1)	
NHL	8	1.1	0.5	0.6 (0.5-0.7)	
(C82-85)		1.1	0.5	0.6 (0.5-0.7)	
Mult myeloma	-	1.2	0.3	0.9 (0.8-0.9)	
(C90)		1.0	0.4	0.6 (0.5-0.7)	
Leukemia		0.8	0.4	0.4 (0.3-0.4)	
(C91-95)		1.1	0.4	0.7 (0.6-0.8)	
Total	a	0.9 0.8	0.5 0.5	0.5 (0.4-0.5) 0.3 (0.2-0.3)	
	0 10 20 30 40 50 Prevalence)			
1 year CS	6	•	1 y	ear GPC	

Other chronic respiratory disease

Cancer site (ICD10)		Prevalence CS GPC		Difference	
Oral Cavity (C00-06)	→		12.1 10.5	6.1 6.9	5.9 (5.7-6.1) 3.6 (3.4-3.8)
Oesophageal (C15)	0-E		14.1 14.4	8.3 10.4	5.8 (5.5-6.0) 4.1 (3.8-4.3)
Stomach (C16)	• - •		13.8 15.6	9.3 10.4	4.5 (4.3-4.8) 5.1 (4.8-5.4)
Colorectal (C18-C20)	e 8		9.6 9.9	8.2 9.6	1.3 (1.1-1.5) 0.3 (0.1-0.6)
Liver (C22)	0-E		13.4 11.8	7.7 7.3	5.6 (5.4-5.9) 4.4 (4.2-4.7)
Pancreas (C25)	•		9.8 10.5	7.6 9.1	2.2 (2.0-2.4) 1.4 (1.2-1.6)
Lung (C34)	•		39.9 44.0	8.9 10.7	30.9 (30.6-31.2) 33.3 (33.0-33.7)
Mal melanoma (C43)			4.5 4.8	5.5 6.1	-1.0 (-1.10.8) -1.4 (-1.61.2)
Breast (C50)	a		5.2 5.9	4.8 5.7	0.4 (0.3-0.5) 0.2 (0.0-0.4)
Cervix (C53)	•		3.6 2.3	2.7 3.4	0.9 (0.8-1.0) -1.2 (-1.31.0)
Uterus (C54-55)	■● ⊡-0		4.0 4.6	6.2 7.5	-2.2 (-2.42.1) -2.9 (-3.12.7)
Ovaries (C56)	e		5.1 5.7	4.6 6.0	0.5 (0.3-0.6) -0.3 (-0.50.2)
Prostate (C61)			10.1 11.8	9.9 11.6	0.2 (0.0-0.4) 0.2 (-0.0-0.5)
Kidney (C64)	e mi		10.9 10.7	7.7 8.9	3.2 (3.0-3.4) 1.8 (1.6-2.0)
Bladder (C67)	•		13.0 15.5	9.4 10.8	3.6 (3.4-3.8) 4.6 (4.4-4.9)
Brain/CNS (C71-72)			3.6 3.0	4.3 4.4	-0.6 (-0.80.5) -1.4 (-1.61.3)
Thyroid (C73)			3.7 3.5	3.2 3.9	0.5 (0.3-0.6) -0.5 (-0.60.3)
NHL (C82-85)	ee oe		8.2 9.6	6.4 7.3	1.8 (1.7-2.0) 2.3 (2.0-2.5)
Mult myeloma (C90)	9 11		10.3 14.1	8.2 10.0	2.1 (1.9-2.3) 4.0 (3.8-4.3)
Leukemia (C91-95)			8.8 10.0	7.6 9.0	1.2 (1.0-1.4) 1.0 (0.8-1.3)
Total	e e		9.7 9.5	7.2 8.4	2.5 (2.3-2.7) 1.1 (0.9-1.3)
	0 10 20	30 40 50 Prevalence			

Chronic kidney disease


Cancer site (ICD10)	Prevalence CS GPC	Difference
Oral Cavity (C00-06)	12.4 11.6 16.0 16.4	0.8 (0.5-1.0) -0.4 (-0.60.1)
Oesophageal (C15)	19.8 14.0 22.0 20.6	5.8 (5.5-6.1) 1.4 (1.1-1.7)
Stomach (C16)	22.3 16.1 24.0 22.7	6.2 (5.9-6.4) 1.3 (0.9-1.6)
(C18-C20)	17.8 15.2 23.5 22.1	2.6 (2.3-2.8) 1.5 (1.1-1.8)
(C22)	24.2 15.7 27.1 19.3	8.5 (8.2-8.7) 7.8 (7.4-8.1)
Pancreas (C25) G-D	20.8 15.5 24.1 20.5	5.4 (5.1-5.6) 3.6 (3.3-3.9)
(C34)	23.3 16.0 26.6 21.2	7.4 (7.1-7.7) 5.4 (5.0-5.7)
(C43)	12.0 11.4 14.6 14.5	0.6 (0.4-0.8) 0.2 (-0.1-0.4)
Breast (C50)	11.1 10.9 14.9 14.9	0.1 (-0.1-0.4) 0.0 (-0.3-0.3)
Cervix (C53)	6.1 4.5 7.3 7.1	1.6 (1.5-1.8) 0.2 (0.0-0.4)
(C54-55)	15.8 13.3 21.5 19.2	2.6 (2.3-2.8) 2.3 (2.0-2.6)
Ovaries (C56) OPE	12.8 10.2 17.8 15.0	2.6 (2.4-2.8) 2.8 (2.5-3.1)
Prostate (C61)	17.7 15.2 23.8 22.7	2.5 (2.2-2.7) 1.1 (0.8-1.4)
Kidney (C64)	29.0 13.9 50.1 18.3	15.1 (14.8-15.3) 31.7 (31.4-32.1)
Bladder (C67)	20.2 16.0 26.9 22.6	4.2 (4.0-4.5) 4.3 (3.9-4.6)
Brain/CNS (C71-72)	8.7 5.6 8.7 8.2	3.1 (3.0-3.3) 0.5 (0.3-0.8)
Thyroid (C73) O-E	8.3 6.5 12.3 9.4	1.8 (1.6-2.0) 3.0 (2.7-3.2)
NHL (C82-85)	16.4 12.4 19.8 17.4	3.9 (3.7-4.1) 2.4 (2.1-2.8)
Mult myeloma (C90)	27.4 14.8 31.3 19.8	12.5 (12.3-12.8) 11.5 (11.1-11.9)
(C91-95)	17.7 14.4 23.9 19.4	3.2 (3.0-3.5) 4.6 (4.2-4.9)
Total	16.2 13.3 20.5 18.6	2.8 (2.6-3.1) 1.8 (1.5-2.2)
0 10 20 30 40 50 Prevalence		
5 year CS		• 5 year GPC

CS > GPC (reasonable evidence)


-

weak evidence or no difference

Diabetes



Chronic heart disease



Cancer site (ICD10)			alence GPC	Differenc
Oral Cavity		15.7	23.5	-7.8 (-8.17
(C00-06)		18.9	23.7	-4.8 (-5.14
Oesophageal		15.6	22.1	-6.5 (-6.86
(C15)		14.4	22.3	-7.9 (-8.27
Stomach		14.6	21.5	-6.9 (-7.16
(C16)		12.6	22.9	-10.3 (-10.6
Colorectal		20.0	22.1	-2.2 (-2.41
(C18-C20)		24.0	22.4	1.7 (1.3-2
Liver		23.1	24.4	-1.3 (-1.51
(C22)		21.2	23.9	-2.7 (-3.12
Pancreas		13.7	22.9	-9.2 (-9.49
(C25)		13.0	22.4	-9.5 (-9.79
Lung		17.1	23.1	-6.0 (-6.35
(C34)		22.0	23.3	-1.2 (-1.60
Mai melanoma		21.5	22.1	-0.6 (-0.80
(C43)		21.4	22.7	-1.3 (-1.61
Breast	•	24.1	23.6	<mark>0.5 (0.2-0</mark>
(C50)		24.7	24.7	0.0 (-0.3-0
Cervix	ee ee	22.5	22.3	0.2 (-0.1-0
(C53)		26.0	24.0	2.0 (1.7-2
Uterus		47.3	25.6	21.7 (21.4-22
(C54-55)		46.5	26.4	20.1 (19.8-20
Ovaries	en	25.0	23.0	2.0 (1.7-2
(C56)	e-e	27.9	24.8	3.1 (2.7-3
Prostate		18.8	20.3	-1.5 (-1.71
(C61)		20.6	20.0	0.6 (0.3-0
Kidney	9E	28.4	22.6	5.8 (5.5-6
(C64)		31.1	22.6	8.5 (8.1-8
Bladder	(E)	21.1	20.7	0.5 (0.2-0
(C67)		22.4	21.0	1.4 (1.0-1
Brain/CNS	G -0	22.7	21.4	1.4 (1.1-1
(C71-72)		20.7	24.3	-3.5 (-3.83
Thyroid	•	26.6	23.0	3.6 (3.3-3
(C73)		26.0	24.8	1.3 (0.9-1
NHL		18.9	22.6	-3.7 (-4.03
(C82-85)		21.1	22.8	-1.7 (-2.01
Mult myeloma	1 0	20.2	22.5	-2.3 (-2.62
(C90)		21.6	22.9	-1.3 (-1.60
Leukemia		20.9	21.9	-1.0 (-1.20
(C91-95)		22.1	22.7	-0.6 (-0.90
Total	G	21.8 23.8	22.3 22.9	-0.5 (-0.80 0.9 (0.5-1
0	10 20 30 40	50		

Oheelte

Chronic neurological conditions

Cancer site (ICD10)		Prevalence CS GPC		Difference	
Oral Cavity (C00-06)			7.4 10.5	8.1 8.7	-0.8 (-0.90.6) 1.7 (1.5-2.0)
Oesophageal (C15)	e		12.8 12.4	9.6 11.9	3.1 (2.9-3.3) 0.5 (0.3-0.8)
Stomach (C16)	-		12.1 13.3	11.8 13.2	0.4 (0.2-0.6) 0.1 (-0.2-0.4)
Colorectal (C18-C20)			10.3 11.7	10.2 11.8	0.1 (-0.1-0.3) -0.1 (-0.3-0.2)
Liver (C22)	● ■ 0 - E		13.2 14.1	9.2 10.4	4.0 (3.7-4.2) 3.7 (3.5-4.0)
Pancreas (C25)	•		9.1 11.1	8.6 10.0	0.5 (0.3-0.7) 1.1 (0.8-1.3)
Lung (C34)	● Ⅲ 0+⊡		13.3 14.5	10.6 11.9	2.7 (2.5-2.9) 2.6 (2.3-2.9)
Mal melanoma (C43)	B		6.6 6.9	6.9 7.4	-0.3 (-0.50.1) -0.5 (-0.80.3)
Breast (C50)	8		6.4 6.6	5.9 6.8	0.6 (0.4-0.7) -0.1 (-0.3-0.1)
Cervix (C53)	8		2.9 4.2	3.2 4.1	-0.3 (-0.40.2) 0.0 (-0.1-0.2)
Uterus (C54-55)			6.5 7.8	6.6 7.9	-0.1 (-0.3-0.0) -0.2 (-0.4-0.0)
Ovaries (C56)	e B		5.9 6.0	5.2 6.5	0.6 (0.5-0.8) -0.5 (-0.70.3)
Prostate (C61)	•		11.5 13.9	12.3 14.4	-0.8 (-1.00.6) -0.5 (-0.80.2)
Kidney (C64)	0-E		11.2 12.1	8.7 9.6	2.5 (2.3-2.7) 2.5 (2.3-2.8)
Bladder (C67)			12.6 13.9	11.8 13.1	0.8 (0.6-1.0) 0.8 (0.5-1.1)
Brain/CNS (C71-72)			19.3 21.7	4.6 5.2	14.8 (14.5-15.0) 16.5 (16.2-16.8)
Thyroid (C73)			5.0 4.6	4.3 4.5	0.7 (0.6-0.8) 0.2 (-0.0-0.3)
NHL (C82-85)			8.9 10.2	8.3 9.3	0.6 (0.5-0.8) 1.0 (0.7-1.2)
Mult myeloma (C90)	••••••••••••••••••••••••••••••••••••••		11.4 16.1	9.6 11.0	1.8 (1.6-2.0) 5.1 (4.8-5.4)
Leukemia (C91-95)			10.9 10.4	9.4 10.7	1.4 (1.2-1.6) -0.3 (-0.60.1)
Total	-		9.4 10.1	8.9 10.0	<mark>0.6 (0.4-0.8)</mark> 0.1 (-0.1-0.3)
	0 10 20	30 40 50 Prevalence			

CS > GPC (reasonable evidence)

5 year CS

weak evidence or no difference